

07/31/2009

Survey Questions for Attendees at Relevant Scientific Meetings and Non-Users of the Molecular Libraries Screening/Probes Production Centers Network

*Public reporting burden for this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. **An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.** Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0476). Do not return the completed form to this address.*

A. Network Customer Satisfaction: How well is the network serving the needs of the community?

1. What is the satisfaction level of assay & compound providers with the MLSCN/MLPCN?
 - a) What level of interest has the broader community (non-network users) demonstrated in the MLSCN/MLPCN data & probes?

2. What are the challenges for entering assays and/or compounds into the ML?
 - a) Are you familiar with the MLSCN/MLPCN?
 - b) What are the core features of the MLSCN/MLPCN that must be maintained or enhanced?
 - c) What are the challenges (or your thoughts) with the intellectual property (IP) & data sharing policy?
 - d) What are the challenges (or your thoughts) with the requirement for assays to be HTS-ready or nearly ready?
 - e) What are the challenges (or your thoughts) with the availability of funding for reagent production/secondary screening?
 - f) What are the challenges (or your thoughts) with the amount of time & effort required to write an application for access to the MLSCN/MLPCN?
 - g) What are the challenges (or your thoughts) with the amount of time/compensation to prepare compounds and datafiles for submission to the compound repository?
 - h) What are the challenges (or your thoughts) with the amount of time from submission of compounds until results are obtained from screening center?
 - i) What are the challenges (or your thoughts) with the amount of time from submission of application until results are obtained from screening center?
 - j) What specific approaches or concepts would address any of the challenges above?

3. What capabilities would you like the network to offer that it does not?

- a) What area(s) of biology do you feel have not been adequately explored with small molecules (target classes or cellular phenotypes)?
- b) Are there other capabilities that you would like the network to offer that it does not have?

B. Data Dissemination: Has data dissemination been effective?

1. Do biologists actively use & value PubChem?
 - a) Have there been improvements in the retrieval & browsing tools for PubChem?
 - b) What is your level of satisfaction with PubChem?
2. Do biologists actively use & value MICAD?
 - a) Have there been improvements in retrieval & browsing tools for MICAD?
 - b) What is the user community's level of satisfaction with MICAD?

C. Probes & Probe Reports: What is the usefulness of the probes produced?

1. Do the probes produced reflect the state of the art in probe development/production?
 - a) What is the current or potential application of MLSCN/MLPCN data and probes to your research?
 - b) What is the current or potential application of MLSCN/MLPCN data and probes to the broader research community?
2. What number of produced probes is available to the broader user community?
3. What number of produced probes has been made commercially available?
4. What number of compounds/probes identified through the MLI has been requested by users?

D. Respondent's Background Information

1. Scientific Background
 Biology Chemistry Informatics
2. Affiliation
 - a) Type of Institution
Academic
 Private
 State
 Research Institute
 Foundation
Government Agency
 NIH
 FDA
 CDC
 DOE
 VA
Private Entity
 Small Business
 Pharmaceutical Company
 Hospital
 Biotechnology Company
 Non-Profit

Other (please specify) _____

b) If you are replying on behalf of a group (department, network, society, etc.), please specify the group you are representing: _____

3. Funding Sources

a) NIH Grantee:

Current Past Not a NIH Grantee

b) Other Funding Sources (check all that apply):

Research Institute

Foundation

Pharmaceutical Company

Biotechnology Company

Government Agency Other Than NIH:

FDA

CDC

DOE

VA

Other (please specify) _____

4. Contact Information

(Note: This is optional and not essential for the survey, and will be used only if NIH staff needs to contact a respondent to clarify any responses.)

Name (first, last): _____

Phone: (_____) _____ - _____

Email: _____

Institution: _____

Address: _____

City: _____

State: _____ Zip Code: _____